Comparing two blood filtering methods' effect on clotting
Part of Blood & lymphatic, Heart & circulation clinical trials.
This study compares two ways of filtering your blood (plasmapheresis) to see how each affects your blood's ability to clot. If you already receive regular plasmapheresis with citrate, you might help doctors learn which method is safer for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You get regular plasmapheresis (blood filtering) treatments at least every 10 days.
- Your plasmapheresis uses citrate to prevent clotting during treatment.
- You do not take blood thinners (like warfarin, apixaban, or aspirin).
- You are not being treated for high cholesterol, high triglycerides, blood thickness, acquired hemophilia, or nephrotic syndrome.
- You are not pregnant, breastfeeding, or in another study's exclusion period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new plasma filter, PX2, used in a procedure called therapeutic plasma exchange (TPE) to clean harmful substances from your blood. It’s for people who already need TPE and can safely use a blood thinner during the treatment.
This study compares two blood-clotting medicines used during liver transplant surgery. The goal is to see which one works better to control bleeding and keep you safe during the operation.
This trial tests whether filtering your blood with a special device soon after a stroke clot is removed can improve recovery. It is for people who have had a large vessel stroke in the front part of the brain and have had a successful clot removal procedure.
This study compares two blood-thinning medications used during continuous dialysis for acute kidney injury: one uses citrate (a chemical that prevents clotting) and the other uses heparin (a standard blood thinner). By looking at how well these treatments work, the study aims to find the safest and most effective way to keep the dialysis filter working.
This trial uses stored blood samples to see how well different lab tests measure clotting when someone has a factor deficiency (like low levels of clotting proteins) or liver damage. It may help doctors choose the most accurate test for these situations.
This trial compares different blood test reagents to see which works best for measuring clotting time in people with clotting factor deficiencies or liver disease. It may help doctors choose the right test for your condition.
Hear when a new Hyperfibrinogenemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.